J Korean Med Sci.  2016 Sep;31(9):1505-1506. 10.3346/jkms.2016.31.9.1505.

The Author's Response: Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer

• Paik WH
• Kim YT

• KMID: 2468288
• DOI: http://doi.org/10.3346/jkms.2016.31.9.1505

Abstract

No abstract available.

MeSH Terms

*Chemoradiotherapy
Combined Modality Therapy
Humans
Neoplasm Staging
Pancreatic Neoplasms/*drug therapy

Reference

1. Paik WH, Lee SH, Kim YT, Park JM, Song BJ, Ryu JK. Objective assessment of surgical restaging after concurrent chemoradiation for locally advanced pancreatic cancer. J Korean Med Sci. 2015; 30:917–923.

2. Loehrer AP, Ferrone CR. Treatment of locally advanced pancreatic ductal adenocarcinoma. Dig Surg. 2016; 33:343–350.

3. Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015; 22:1153–1159.

4. Hackert T, Ulrich A, Büchler MW. Borderline resectable pancreatic cancer. Cancer Lett. 2016; 375:231–237.

5. Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, Mohile SG, Mumber M, Schulick R, Shapiro M, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. Forthcoming 2016.

6. Park DI, Lee JK, Kim JE, Hyun JG, Shim SG, Lee KT, Palk SW, Rhee JC, Choi KW, Lim JH, et al. The analysis of resectability and survival in pancreatic cancer patients with vascular invasion. J Clin Gastroenterol. 2001; 32:231–234.

7. Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, et al. A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol. 2010; 17:194–205.

8. Nanda RH, El-Rayes B, Maithel SK, Landry J. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. J Surg Oncol. 2015; 111:1028–1034.

9. Christians KK, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, Kelly T, Erickson B, Wang H, Evans DB, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014; 19:266–274.

10. Satoi S, Fujii T, Yanagimoto H, Motoi F, Kurata M, Takahara N, Yamada S, Yamamoto T, Mizuma M, Honda G, et al. Multicenter phase II study of intravenous and intraperitoneal paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients with peritoneal metastasis. Ann Surg. Forthcoming 2016.